CN88102373A - 苯并咪唑衍生物及其制备方法 - Google Patents
苯并咪唑衍生物及其制备方法 Download PDFInfo
- Publication number
- CN88102373A CN88102373A CN88102373.6A CN88102373A CN88102373A CN 88102373 A CN88102373 A CN 88102373A CN 88102373 A CN88102373 A CN 88102373A CN 88102373 A CN88102373 A CN 88102373A
- Authority
- CN
- China
- Prior art keywords
- meaning
- represented compound
- carbon atom
- group
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title claims 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 17
- 239000002253 acid Chemical class 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- -1 dimethylaminopropyl group Chemical group 0.000 claims abstract description 9
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 7
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 52
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical group [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 150000008065 acid anhydrides Chemical class 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 1
- 239000000043 antiallergic agent Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000004430 oxygen atom Chemical class O* 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 23
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000005192 partition Methods 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 125000004494 ethyl ester group Chemical group 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- BNJMRELGMDUDDB-UHFFFAOYSA-N $l^{1}-sulfanylbenzene Chemical compound [S]C1=CC=CC=C1 BNJMRELGMDUDDB-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- ICNCMCHAPLUNBG-UHFFFAOYSA-N propyl carbamodithioate Chemical compound CCCSC(N)=S ICNCMCHAPLUNBG-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 150000002617 leukotrienes Chemical class 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- DCRZVUIGGYMOBI-UHFFFAOYSA-N 2-sulfanylidene-1,3-dihydrobenzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=S)NC2=C1 DCRZVUIGGYMOBI-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 2
- QRNATDQRFAUDKF-UHFFFAOYSA-N 2-carbamothioylsulfanylethyl carbamodithioate Chemical compound NC(=S)SCCSC(N)=S QRNATDQRFAUDKF-UHFFFAOYSA-N 0.000 description 2
- LMQBMWHHGVZWMR-UHFFFAOYSA-N 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyl-1-benzopyran-2-carboxylic acid Chemical compound C1=CC(C(C)=O)=C(O)C(CCC)=C1OCC(O)COC1=CC=C2C(=O)C=C(C(O)=O)OC2=C1CCC LMQBMWHHGVZWMR-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- WAUHABGEEBVFTF-UHFFFAOYSA-N CCCC[S] Chemical compound CCCC[S] WAUHABGEEBVFTF-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- YHMYGUUIMTVXNW-UHFFFAOYSA-N 1,3-dihydrobenzimidazole-2-thione Chemical compound C1=CC=C2NC(S)=NC2=C1 YHMYGUUIMTVXNW-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- WTLNOANVTIKPEE-UHFFFAOYSA-N 2-acetyloxypropanoic acid Chemical compound OC(=O)C(C)OC(C)=O WTLNOANVTIKPEE-UHFFFAOYSA-N 0.000 description 1
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- YVHPHQBRUPLYOS-UHFFFAOYSA-N dichloromethane;methane Chemical compound C.ClCCl YVHPHQBRUPLYOS-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- UJQMLHKSZKBMMO-UHFFFAOYSA-N n,n-diethylethanamine;pyridine Chemical compound C1=CC=NC=C1.CCN(CC)CC UJQMLHKSZKBMMO-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WIYDEVSKVYFPPV-UHFFFAOYSA-N pentanamide;hydrochloride Chemical compound Cl.CCCCC(N)=O WIYDEVSKVYFPPV-UHFFFAOYSA-N 0.000 description 1
- 125000005359 phenoxyalkyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
一种以下通式的苯并咪唑衍生物,其中R1表示氢原子、具有1~6碳原子的低级烷基或二甲氨基丙基,R2表示氢原子或具有1~3碳原子的低级链烷醇基团,R3表示氢原子、具有1~3碳原子的低级烷基或具有1~3碳原子的低级链烷醇基团,X表示硫原子、亚硫酰基、磺酰基、氨基或亚甲基,A表示具有1~12个碳原子的链烯基,Y表示氧原子或硫原子;它们的酸式盐或碱式盐及其水合物。这是一种有用的抗过敏剂。
Description
本发明涉及某些新颖的具有强的和选择性的抗-白三烯(anti-Leukstriene)作用的、且能有效地预防或治疗变应性疾病如哮喘的苯并咪唑衍生物,还涉及它们的中间体及其制备方法。
更具体说,本发明涉及某些新颖的、化学式(Ⅰ)的苯并咪唑衍生物
其中R1表示氢原子、具有1~6个碳原子的低级烷基或二甲氨基丙基,R2表示氧原子或具有1~3个碳原子的低级链烷酵基团(alkanoyl gloup),R3表示氢原子、具有1~3个碳原子的低级烷基或具有1~3个碳原子的低级链烷醇基团,X表示硫原子、亚硫酰基、磺酰基、氨基或亚甲基。A表示具有1~12个碳原子的链烯基,该链烯基能被羟基或具有1~3个碳原子的低级烷基
(其中,R′和R″各为独立的氢原子、具有1~3个碳原子的低级烷基或羟基,而n和m等于0、1、2或3)任意地取代,Y表示氧原子或硫原子;它们的酸式盐或碱式盐及其水合物。
通过5-脂肪氧合酶途径的花生四烯酸的代谢物白三烯(白三烯C4、D4和E4)是SRS-A(过敏症的慢反应物)的组份,是直接型变应性疾病如支气管性气喘的重要介质。由于这一原因,能拮抗白三烯的药物可被用于治疗支气管性气喘。然而,通过内用能显示这些效果的药物还未为人们所知。
在先前的专利中,本发明者已经发现由通式(以下所描述)所表示的化合物对白三稀引起的支气管缩小具有强烈的抑制作用(日本专利公开61-186368,相应于欧洲专利申请0121806)
经过努力研究,本发明者发现由通式(Ⅰ)所表示的化合物对白三烯引起的支气管缩小具有很强的选择性的抑制作用。
由下列通式(Ⅰ)所表示的苯并咪唑衍生物,
其中R1表示氢原子、具有1~6个碳原子的低级烷基或二甲氨基丙基,R2表示氢原子或具有1~3个碳原子的低级链烷醇基团,R3表示氢原子、具有1~3个碳原子的低级烷基或具有1~3个碳原子的低级链烷醇基团,X表示硫原子、亚硫酰基、磺酰基、氨基或亚甲基,A表示具有1~12个碳原子的链烯基,该链烯基可被羟基或具有1~3个碳原子的低级烷基即
(其中,R′和R″各为独立的氢原子、具有1~3个碳原子的低级烷基或羟基,n和m等于0、1、2或3)任意地取代,Y表示氧原子或硫原子、它们的酸式盐或碱式盐及其水合物。
根据本发明,由通式(Ⅰ)所代表的化合物是通过如下途径进行制备的。
(1)通式(Ⅰ)中X为硫原子和R1为氢原子的化合物可通过使通式(Ⅲ)或(Ⅲ′)所表示的苯氧基烷基衍生物与通式(Ⅱ)的化合物进行反应来制备。典型地,它们可以在碱如碳酸钾、碳酸钠、氢氧化钾等的存在下,通过使苯氧基衍生物(Ⅲ)在合适的溶剂如二甲基甲酰胺、二甲亚砜、醇等之中与通式(Ⅱ)的化合物进行反应来制备。
其中R1和R3同上所述。
其中A和Y同上所述,Z表示离去基团
(2)通式(Ⅰ)中X为亚甲基的化合物也可通过使由通式(Ⅴ)所表示的苯氧基衍生物与通式(Ⅳ)所表示的化合物进行反应来制备。典型地,它们可在合适溶剂如甲醇、乙醇等的存在下使苯氧基衍生物(Ⅴ)与通式(Ⅳ)的化合物进行反应来制备,然后在搅拌条件下用碱性溶液如氢氧化钾、氢氧化钠等进行加热。
其中R1同上所述。
其中R2、A和Y同上所述,R4表示具有1~6个碳原子的低级烷基。
(3)通式(Ⅰ)中X为亚硫酰基的化合物可通过对通式(Ⅰ)中X为硫原子的化合物进行氧化来制备。典型地,它们可在合适溶剂如二氯甲烷、醇等的存在下使通式(Ⅰ)中X为硫原子的化合物与等量或过量弱氧化剂如间-氯过苯甲酸、过氧化氢等进行反应来制备。
(4)通式(Ⅰ)中X为磺酰基的化合物可通过对通式(Ⅰ)中X为硫原子的化合物进行氧化来制备。典型地,它们可通过使通式(Ⅰ)中X为硫原子的化合物与相同于(3)中的二倍或更过量的弱氧化剂进行反应来制备。
(5)通过使通式(Ⅰ)中R2为氢原子的酯化化合物,在惰性溶剂如二氯甲烷或氯仿中,在过量碱例如吡啶三乙胺或4-二甲基氨基吡啶或仅仅为吡啶的存在下,与酰基剂如酰卤或酸酐进行反应来制备通式(Ⅰ)中R2为低级链烷醇基团的化合物。
其中R1、R2、R3、X、A和Y同上所述。
此外,由通式(Ⅰ)所代表的化合物可通过用酸或碱进行处理被转化成盐。这些酸可以是无机酸,例如盐酸、硫酸、磷酸等,或者是有机酸如甲磺酸、乳酸、乙酸、柠檬酸、酒石酸等等。碱可以是碱金属如钠、钾等等。
由通式(Ⅴ)所表示的化合物是新的化合物,且可从通式(Ⅵ)所表示的化合物来制备。典型地,它们在合适溶剂中如乙醚等中并在搅拌的条件下通过使盐酸与通式(Ⅵ)的化合物和醇进行反应来制备。
其中R2、R4、A和Y同上所述。
其中R2、A和Y同上所述。
以下,本发明将在具体实施例的基础上得到说明,但本发明不限于这些实施例。
实施例1
2-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙基硫代]苯并咪唑-5-羧酸
30毫升乙醇中的2-巯基苯并咪唑-5-羧酸(3.25克)、3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙基溴(2.00克)和氢氧化钾(1.27克)的混合物被回流4小时。然后,该反应混合物被注入到冰水中,用浓盐酸使之酸化,并用乙酸乙酯进行萃取。接着,在无水硫酸钠上对有机层进行干燥,再进行蒸发。此后用硅胶柱色谱分离法对所生成的残留物加以提纯,用二氯甲烷-乙酸乙酯-甲醇(10∶2∶1)进行洗脱,用正己烷-乙酸乙酯进行再结晶之后就得到了一种浅黄色晶体的目的化合物(3.00克,67.1%),熔点为106~108℃
对C22H24N2O5S的分析(%):计算(实测);
C,61.67(61.76);H,5.65(5.89);N,6.54(6.26)
实施例2
2-[2-(4-乙酰基-3-羟基-2-丙基苯氧基)乙基硫代]苯并咪唑-5-羧酸
30毫升N,N-二甲基甲酰胺中的2-(4-乙酰基-3-羟基-2-丙基苯氧基)乙基溴(2.71克)、2-巯基苯并咪唑-5-羧酸乙酯(2.00克)和无水碳化钾(1.49克)的混合物在80~90℃下被搅拌30分钟。然后,该反应混合物被倒入冰水中,用浓盐酸进行酸化,再用乙酸乙酯进行萃取。接着,用水洗涤有机层,在无水硫酸钠上进行干燥,再进行蒸发。此后,用硅胶柱色谱分离法对生成的残留物加以提纯,用二氯甲烷-乙酸乙酯(10∶1)进行洗脱,从而得到一种黄色油状的2-[2-(4-乙酰基-3-羟基-2-丙基苯氧基)乙基硫代]苯并咪唑-5-羧酸乙酯(2.33克,58.5%)。
把上述酯(2.20克)加入到1N的氢氧化钠溶液(20毫升)中,然后该混合物被回流30分钟,接着注入到冰水中,用浓盐酸进行酸化,再用乙酸乙酯进行萃取。此后,用水洗涤有机层,在无水硫酸钠上进行干燥,再进行蒸发。接着,再用硅胶柱色谱分离法对所生成的残留物加以提纯,用二氯甲烷-甲醇(10∶1)进行洗脱,用正己烷-乙酸乙酯加以再结晶之后就得到了一种无色晶体的目的化合物(1.60克,77.1%),熔点为108~110℃。
对C21H22N2O5S的分析:计算(实测);
C,60.86(60.65);H,5.35(5.35);N,6.76(6.61)
实施例3
2-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)-2-羟基丙基硫代]苯并咪唑-5-羧酸
按照与实施例2类似的方法用3-(4-乙酰基-3-羟基-2-丙基苯氧基)-1,2-环氧丙烷(1.91克)和2-巯基苯并咪唑-5-羧酸乙酯(1.70克)制备了2-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)-2-羟基丙基硫代]苯并咪唑-5-羧酸乙酯。获得的2.10克(58.1%)酯是一种黄色的油。按照与实施例2相同的方法再把该酯(2.10克)转化成目的化合物(870毫克,44.1%),它是一种浅黄色晶体,熔点为133~135℃。
对C22H24N2O6S的分析:计算值(实测);
C,59.45(59.94);H,5.44(5.60);N,6.30(6.23)。
实施例4
2-[3-(3-乙酰氧基-4-乙酰基-2-丙基苯氧基)丙基硫代]苯并咪唑-5-羧酸
50毫升二氯甲烷中的2-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙基硫代]苯并咪唑-5-羧酸(1.50克)、三乙胺(4毫升)、乙酐(4毫升)和4-二甲氨基吡啶(100毫克)的混合物在0℃然后在室温下被搅拌达5小时。以后,往混合物中加入甲醇(4毫升),再进一步搅拌达30分钟,接着对该混合物进行蒸发。然后用水洗涤残留物,并使之溶解在乙醇中,再浓缩至干燥。用硅胶柱色谱分离法对该残留物加以提纯,用二氯甲烷-乙酸乙酯-甲醇(10∶2∶1)进行洗脱,再用正己烷-氯仿对此作再结晶之后就获得了一种黄色晶体的目的产物(970毫克,58.2%),熔点为85~87℃。
对C24H26N2O2S·1/3H2O的分析:计算(实测);
C,60.49(60.64);H,5.64(5.78);N,5.88(5.72)。
实施例5
2-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙基亚硫酰基)苯并咪唑-5-羧酸
往30毫升二氯甲烷和3毫升甲醇中的2-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙基硫代]苯并咪唑-5-羧酸(1.00克)的混合物(在冰-盐-水浴中受到搅拌)中小批量地加入低于0℃的间-氯过苯甲酸(80%,503毫克)。再搅拌15分钟后对该混合物进行蒸发,接着用硅胶柱色谱分离法提纯该残留物,用二氯甲烷-乙酸乙酯-甲醇(10∶2∶1)进行洗脱,再用乙醇-水作再结晶之后就获得了一种无色晶体的目的化合物(540毫克,52.1%),熔点为173~175℃。
对C22H24N2O6S的分析:计算值(实测);
C,59.45(59.61),H,5.44(5.46);N,6.30(6.30)。
实施例6
2-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙基磺酰基]苯并咪唑-5-羧基
往30毫升二氯甲烷和3毫升甲醇中的2-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙基硫代]苯丙咪唑-5-羧酸(1.08克)的混合物(在5~10℃下接受着搅拌)中小批量地加入间-氯过苯甲酸(80%,1.20克)。再搅拌15分钟之后对该混合物进行蒸发,接着用硅胶柱色谱分离法对所生成的残留物加以提纯,用二氯甲烷-乙酸乙酯-甲醇(10∶2∶1)进行洗脱,再用乙醇-水作再结晶之后就获得了一种无色晶体的目的化合物(890毫克,76.7%),熔点为212~215℃(分解)
对C22H24N2O7S的分析:计算值(实测);
C,57.38(57.50);H,5.25(5.27);N,6.08(6.09)。
实施例7~31
按照与实施例1~6中相同的程序制备的其它新化合物被列在表1。
表1(2)
*1:2/3H2O,*2:1H2O,*3:1HCl·1/2H2O,*4:1Na·1/5H2O,*5:1/3H2O,*6:2草酸,*7:E型,*8:Z型,*9:1HCl,*10:6/5H2O
实施例32
5-(4-乙酰基-3-羟基-2-丙基苯氧基)戊酰亚胺盐氢氯化物[5-(4-Acetyl-3-hydroxy-2-propylphenoxy)pentanimidate hydrochloride]
往30毫升乙醚中的5-(4-乙酰基-3-羟基-2-丙基苯氧基)戊腈(5.5克)和乙醇(0.95毫升)的混合物(在冰-盐-水浴中接受冷却)中鼓入氯化氢达20分钟(0℃以下)。然后在同样的温度下,使所生成的溶液静置30分钟,并在冰箱中静置一夜。以后,在减压的条件下蒸发该混合物,并用无水乙醚对所生成的残留物进行研制,从而获得目的化合物(4.0克,81.1%),它是一种无色的晶体,熔点为104~105℃。
对C18H27NO4·HCl·1/2H2O的分析:计算(实测);
C,58.93(58.75);H,7.97(7.75);N,3.82(4.02)。
实施例33~35
按照与实施例32中相同的程序制备的其它新化合物(实施例33~35)被列在表2
*:1/8H2O
实施例26
2-[4-(4-乙酰基-3-羟基-2-丙基苯氧基)丁基]苯并咪唑-5-羧酸
40毫升乙醇中的5-(4-乙酰基-3-羟基-2-丙基苯氧基)戊酰、胺盐氢氯化物(3.0克)和3,4-二氨基苯甲酸乙酯(1.4克)的混合物在室温下被搅拌24小时。然后,向该混合物中加入氢氧化钠溶液(1.6克/30毫升水)并对所生成的混合物进行40分钟的回流。在减压下除去溶剂之后又把该混合物倒入冰水中,用浓盐酸进行酸化并用乙酸乙酯进行萃取。接着,用水洗涤有机层并在无水硫酸钠上对此进行干燥。以后蒸发该萃取物,用硅胶柱色谱分离法对生成的残留物进行提纯,再用二氯甲烷-乙醇(9∶1)加以洗脱就得到了目的化合物(2.0克,58.1%),它是一种非晶形粉末,熔点为98~100℃。
对C23H26N2O5的分析:计算(实测);
C,67.30(67.14);H,6.38(6.40);N,6.82(6.85)。
实施例37~39
通过与实施例36中相同的程序制备的其它新化合物被列在表3中。
实施例40
2-[4-(4-乙酰基-3-羟基-2-丙基苯基硫)丁基硫代)苯并咪唑-5-羧酸
a)4-[4-乙酰基-3-羟基-2-丙基苯基硫)丁基溴
在1小时内,往100毫升丙酮中的1,4-二溴丁烷(32.9克)、无水碳酸钾(5.25克)和碘化钾(1克)的正在回流的混合物中滴入20毫升丙酮中的2′-羟基-4′-巯基-3′-丙基乙酰苯(8.00克)之溶液,并接受2小时的回流。然后把混合物过滤掉,并把溶剂蒸发掉。接着,通过硅胶色谱分离法对所生成的残留物加以提纯,用苯进行洗脱之后就得到了目的化合物(6.90克,52.6%),它是一种黄色的油。
b)2-[4-(4-乙酰基-3-羟基-2-丙基苯基硫)丁基硫]苯并咪唑-5-羧酸乙酯
20毫升N,N-二甲基甲酰胺中的2-巯基苯并咪唑-5-羧酸乙酯(1.29克)、无水碳酸钾(960毫克)的混合物在60~70℃下被搅拌30分钟。然后,在10分钟内往该混合物中滴入N,N-二甲基甲酰胺(10毫升)和4-(4-乙酰基-3-羟基-2-丙基苯硫代)丁基溴(2.00克)所组成的溶液,并在相同的温度下搅拌30分钟。接着把该混合物注入冰水中,用浓盐酸进行酸化,再用乙酸乙酯进行萃取。以后用水洗涤有机层并在无水硫酸钠上对此进行干燥,再进行蒸发。用硅胶柱色谱分离法对所生成的残留物加以提纯,再用二氯甲烷-乙酸乙酯进行洗脱之后就得到了目的化合物(2.53克,89.8%),它是一种浅黄色油。
c)2-[4-(4-乙酰基-3-羟基-2-丙基苯基硫)丁基硫]苯并咪唑-5-羧酸
30毫升水中的2-[4-(4-乙酰基-3-羟基-2-丙基苯基硫)丁基硫代]苯并咪唑-5-羧酸乙酯(2.50克)、1,4-二噁烷(30毫升)和氢氧化钠(1.03克)的混合物在60℃下被搅拌2小时。然后,该混合物被注入冰水中,用浓盐酸进行酸化,并用乙酸乙酯进行萃取。接着,用水对有机层进行洗涤,在无水硫酸钠上进行干燥,再进行蒸发。用硅胶柱色谱分离法加以提纯后再用二氯甲烷-甲烷(10∶1)进行洗脱,从而得到目的化合物(1.52克,64.5%),它是一种黄色晶体,熔点为90~95℃。
对C22H26N2O4S2的分析:计算(实测);
C,60.24(60.01);H,5.71(5.86);N,6.11(5.93)
本发明的化合物对隔离了的豚鼠回肠的LTD显示了很强的中和作用。再者,值得指出的是在内服时显示了显著的作用。
体重约450克的雄性哈脱莱(Hartley)豚鼠被戊巴比妥钠(30毫克/公斤i.p.)麻醉。在人工通风的条件下,通过修正Konzett-Rossler的方法(J·Harvey等,药物方法杂志,9,147~155,1983)测定了横过肺压(transpulmonary pressure)的变化。用消炎痛(10毫克/公斤,静脉内注射)和心得安(1毫克/公斤,静脉内注射)治疗了动物。通过快速浓注白三烯D4(3微克/公斤,静脉内注射)获得了支气管收缩剂的反应。试验化合物被悬浮在5%的阿拉伯树胶溶液(Cum Arabic Solution)中,并在与白三烯D4作用之前的2小时口服。如表4所示,本发明的化合物以低于参比化合物的口服剂量抑制了支气管收缩剂的反应。
表4
实施例 剂量(毫克/公斤,p.o.) 抑制(%)
1 100 47.8
200 63.3
6 200 40.5
11 25 27.6
50 73.1
100 84.6
12 200 33.3
24 200 57.1
36 100 44.6
200 88.6
参考例1* 400 19.5
*2-[3-(4-乙酰基-3-羟基-2-苯氧基)丙基磺酰基]苯并咪唑(日本专利公开61-186368的实施例11)
人们已悉知,FPL55712,一种典型的白三烯拮抗剂在口服时不显示任何效果(P.Sheard等;专论,过敏反应,第244-248页,S.Karger,1977)
FPL55712
7-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)-2-羟基丙氧基]-4-氧代
-8-丙基-4H-1-苯并吡喃-2-羧酸钠
相应地,本发明的化合物对那些白三烯起了重要作用的疾病如支气管性气喘、变应性鼻炎、变应性结膜炎、荨麻症也是有效的。
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9681887 | 1987-04-20 | ||
JP96818/87 | 1987-04-20 | ||
JP96818/07 | 1987-04-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN88102373A true CN88102373A (zh) | 1988-12-07 |
CN1025191C CN1025191C (zh) | 1994-06-29 |
Family
ID=14175161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN88102373A Expired - Fee Related CN1025191C (zh) | 1987-04-20 | 1988-04-20 | 苯并咪唑衍生物的制备方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US4942245A (zh) |
EP (1) | EP0287971B1 (zh) |
KR (1) | KR950014792B1 (zh) |
CN (1) | CN1025191C (zh) |
AU (1) | AU611144B2 (zh) |
CA (1) | CA1318676C (zh) |
DE (1) | DE3878578T2 (zh) |
ES (1) | ES2053607T3 (zh) |
HU (2) | HU201315B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114716346A (zh) * | 2020-12-15 | 2022-07-08 | 广西师范大学 | 一种4-硝基苯胺衍生物及其应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE106393T1 (de) * | 1987-11-17 | 1994-06-15 | Zeneca Inc | Imidate mit insektizider wirkung. |
DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
BR0009593A (pt) * | 1999-04-06 | 2002-06-18 | Sankyo Co | Agente melhorador de resistência à insulina, agente hipoglicêmico, agente imunorregulador, inibidor de aldose redutase, inibidor de 5-lipoxigenase, supressor de produção de lipìdios peroxidados, ativador de ppar, antagonista de leucotrienos, promotor de formação hidroxiadipocelular ou antagonista de cálcio, agente preventivo e/ou terapêutico, derivados de ácido carboxìlico, medicamento, composição farmacêutica, e, uso de um composto |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111976A (en) * | 1977-12-27 | 1978-09-05 | Ciba-Geigy Corporation | Process for the preparation of methyliminoisobutyrate hydrochloride |
US4440935A (en) * | 1981-07-20 | 1984-04-03 | Usv Pharmaceutical Corporation | Bicycloimidazoles |
DE3216722A1 (de) * | 1982-05-05 | 1983-11-10 | Hoechst Ag, 6230 Frankfurt | 4-halomethylbenzoesaeure-alkylester-imine und verfahren zu deren herstellung |
US4661505A (en) * | 1982-11-03 | 1987-04-28 | Eli Lilly And Company | Leukotriene antagonists |
SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
EP0174717B1 (en) * | 1984-07-06 | 1992-01-22 | FISONS plc | Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors |
PH22520A (en) * | 1984-11-12 | 1988-10-17 | Yamanouchi Pharma Co Ltd | Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them |
JPS61186368A (ja) * | 1985-02-14 | 1986-08-20 | Kyorin Pharmaceut Co Ltd | 新規な抗アレルギ−薬およびその製造方法 |
-
1988
- 1988-04-11 US US07/180,065 patent/US4942245A/en not_active Expired - Lifetime
- 1988-04-14 CA CA000564164A patent/CA1318676C/en not_active Expired - Fee Related
- 1988-04-15 DE DE8888106058T patent/DE3878578T2/de not_active Expired - Fee Related
- 1988-04-15 ES ES88106058T patent/ES2053607T3/es not_active Expired - Lifetime
- 1988-04-15 EP EP88106058A patent/EP0287971B1/en not_active Expired - Lifetime
- 1988-04-18 KR KR1019880004379A patent/KR950014792B1/ko not_active IP Right Cessation
- 1988-04-18 AU AU14734/88A patent/AU611144B2/en not_active Ceased
- 1988-04-19 HU HU881997A patent/HU201315B/hu not_active IP Right Cessation
- 1988-04-19 HU HU903277A patent/HU204796B/hu not_active IP Right Cessation
- 1988-04-20 CN CN88102373A patent/CN1025191C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114716346A (zh) * | 2020-12-15 | 2022-07-08 | 广西师范大学 | 一种4-硝基苯胺衍生物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CA1318676C (en) | 1993-06-01 |
EP0287971A3 (en) | 1989-03-22 |
DE3878578T2 (de) | 1993-09-09 |
HU903277D0 (en) | 1990-10-28 |
AU611144B2 (en) | 1991-06-06 |
HUT49590A (en) | 1989-10-30 |
US4942245A (en) | 1990-07-17 |
ES2053607T3 (es) | 1994-08-01 |
EP0287971A2 (en) | 1988-10-26 |
KR880012564A (ko) | 1988-11-28 |
HU201315B (en) | 1990-10-28 |
CN1025191C (zh) | 1994-06-29 |
EP0287971B1 (en) | 1993-02-24 |
KR950014792B1 (ko) | 1995-12-14 |
DE3878578D1 (de) | 1993-04-01 |
AU1473488A (en) | 1988-10-20 |
HU204796B (en) | 1992-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1083833C (zh) | 用作降胆固醇剂的硫取代的氮杂环丁烷酮类化合物 | |
CN1060472C (zh) | 三环取代异羟肟酸衍生物其制备方法、含有它们的药物及其用途 | |
CN1069098C (zh) | 新的咪唑衍生物及其制备方法 | |
CN1055471C (zh) | 取代的咪唑烷,其制备方法和中间体,其药物组合物和其用途 | |
CN1671695A (zh) | 用作pde4抑制剂的吡咯烷二酮取代的哌啶-2,3-二氮杂萘酮化合物 | |
CN1075811C (zh) | 新型取代的2,4-噻唑烷二酮衍生物,其制备方法以及含有它们的药物组合物 | |
CN1042537A (zh) | 喹诺酮衍生物 | |
CN87107975A (zh) | 治疗药物的制备方法 | |
CN1027506C (zh) | 新的2,9-二取代-4H-吡啶并[1,2-a]嘧啶-4-酮的制备方法 | |
CN1144806C (zh) | 噻吩并嘧啶化合物 | |
CN1060778C (zh) | 头孢菌素衍生物 | |
EP1118610B1 (fr) | Nouveaux dérivés de benzènesulfonamide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
CN1034574C (zh) | 5-氧取代的(rs)-2-(2,3-二氢-4,6,7-三甲基苯并呋喃基)乙酸衍生物的制备方法 | |
CN1067985C (zh) | 吲哚衍生物及含它们的药物 | |
CN88102373A (zh) | 苯并咪唑衍生物及其制备方法 | |
CN1014058B (zh) | 制备2-吡咯烷酮衍生物的方法 | |
CN1299357A (zh) | 主要用于治疗骨质疏松的吲哚衍生物 | |
CN1022241C (zh) | 3-酰基-2-氧代吲哚-1-羧酰胺抗炎剂的前药化合物的制备 | |
CN1070190A (zh) | 杂环取代的喹啉甲氧基苯乙酰胺 | |
CN1127482C (zh) | 含有磺酰基二苯基吲哚化合物及其制法和药物用途 | |
CN1010777B (zh) | 氧杂蒽酮衍生物的制备方法 | |
CN1117091C (zh) | 取代的异噁唑基噻吩化合物 | |
CN1011588B (zh) | 吡啶衍生物的制备方法 | |
CN1025185C (zh) | 苯氧基烷基羧酸衍生物及其制备方法 | |
EP0395526A1 (fr) | Nouveaux dérivés benzothiazolinoniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
C19 | Lapse of patent right due to non-payment of the annual fee |